388
Views
12
CrossRef citations to date
0
Altmetric
Review

Pharmacological management of relapsed/refractory NSCLC with chemical drugs

, , , , &
Pages 295-304 | Received 02 Dec 2016, Accepted 17 Jan 2017, Published online: 29 Jan 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Mariacarmela Santarpia, Niccola Funel, Asif Ali & Elisa Giovannetti. (2018) Liquid biopsies to optimize therapeutic efficacy in unresponsive lung cancer patients. Expert Opinion on Drug Metabolism & Toxicology 14:8, pages 761-763.
Read now
Mariacarmela Santarpia, Alessia Liguori, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla & Rafael Rosell. (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy 8, pages 109-125.
Read now
Chiara Lazzari, Niki Karachaliou, Vanesa Gregorc, Alessandra Bulotta, Maria Gonzalez-Cao, Alberto Verlicchi, Giuseppe Altavilla, Rafael Rosell & Mariacarmela Santarpia. (2017) Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Review of Respiratory Medicine 11:6, pages 469-479.
Read now

Articles from other publishers (8)

Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, Acya Bizieux, Hubert Curcio, Marie Bernardi, Romain Corre, Florian Guisier, Stéphane Hominal, Gwenaelle Le Garff, Olivier Bylicki, Chrystèle Locher, Margaux Geier, Christos Chouaïd & Gilles Robinet. (2023) Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer 178, pages 191-197.
Crossref
Renaud Descourt, Christos Chouaid, Maurice Pérol, Benjamin Besse, Laurent Greillier, Olivier Bylicki, Charles Ricordel, Florian Guisier, Radj Gervais, Roland Schott, Jean-Bernard Auliac, Gilles Robinet & Chantal Decroisette. (2021) First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%. Future Oncology 17:23, pages 3007-3016.
Crossref
Chun-San Tai, Kuan-Chun Lan, Erick Wang, Fu-Erh Chan, Ming-Ting Hsieh, Ching-Wen Huang, Shun-Long Weng, Po-Chun Chen & Wen Liang Chen. (2021) Nanotopography as Artificial Microenvironment for Accurate Visualization of Metastasis Development via Simulation of ECM Dynamics. Nano Letters 21:3, pages 1400-1411.
Crossref
Shuzhen Li, Hua Li, Yajie Cao, Haiying Geng, Fu Ren, Keyan Li, Chunmei Dai & Ning Li. (2021) Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma. Medicine 100:32, pages e26474.
Crossref
Jiarong Bian, Ke Yan, Na Liu & Xingxiang Xu. (2020) Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 146:10, pages 2621-2630.
Crossref
Alain Vergnenegre, Isabelle Monnet, Acya Bizieux, Marie Bernardi, Anne Marie Chiapa, Hervé Léna, Christos Chouaïd & Gilles Robinet. (2020) Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – VinMetAtezo trial, (GFPC ‡ 04-2017) . Future Oncology 16:4, pages 5-10.
Crossref
Aniello Cerrato, Roberta Visconti & Angela Celetti. (2018) The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer. Molecular Cancer 17:1.
Crossref
Jillian Wilhelmina Paulina Bracht, Clara Mayo-de-las-Casas, Jordi Berenguer, Niki Karachaliou & Rafael Rosell. (2018) The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. Current Oncology Reports 20:9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.